Mosca F, Colnaghi M, Agosti M, Fumagalli M
NICU, Department of Clinical Sciences and Community Health, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:68-9. doi: 10.3109/14767058.2012.715003.
Respiratory failure in the premature infants remains a difficult challenge. An alternative to the use of nasal continuous positive airway pressure (NCPAP) as a non-invasive modality to support respiratory distress in premature infants has been the recent introduction of high flow nasal cannula (HFNC) devices in many neonatal units. There has been increased use of HFNC presumably because of anecdotal reports and experience that it is easy to use, and well tolerated by the infants, while experiencing decreased nasal septumerosion. The paucity of evidence regarding its efficacy and safety, would support a caution approach to the use of HFNC. Particular concern has focused on the imprecise regulation and generation of pressure that may occur at higher flows especially in the smallest of infants.
早产儿呼吸衰竭仍然是一项艰巨的挑战。在许多新生儿重症监护病房，最近引入了高流量鼻导管（HFNC）设备，作为一种替代使用鼻持续气道正压通气（NCPAP）的无创方式，来支持早产儿的呼吸窘迫。HFNC的使用有所增加，可能是因为有传闻称其使用方便，婴儿耐受性良好，同时鼻中隔糜烂减少。关于其疗效和安全性的证据不足，这支持在使用HFNC时采取谨慎的方法。特别令人担忧的是，在较高流量时可能会出现压力调节和产生不准确的情况，尤其是在最小的婴儿中。
